Sociedad Americana de Hirudoterapia

National Pharmaceutical Regulatory Agency

NPRA · Malaysia · asia pacific

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Malaysia's National Pharmaceutical Regulatory Agency (under the Ministry of Health) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general medical device framework or traditional and complementary medicine pathways as appropriate.

Regulatory Profile

Agency type
national regulator
Region
asia pacific
Country
Malaysia
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Malaysian national medical device law (Medical Device Act and subsidiary regulations)
  • Malaysian Traditional and Complementary Medicine Act framework

Prescriber Requirements

  • Malaysian Medical Council–registered physician — order required for any biomedical device application
  • Traditional and complementary medicine practitioners registered under the Malaysian framework may have separate scope; specific hirudotherapy authorisation not independently verified by ASH

Supply Chain & GMP

Malaysian medical-device establishment registration as applicable; Bahasa Malaysia and English-language labelling. Standard cold-chain conditions.

Import/Export Rules

Import licence requirements under Malaysian medical-device law; Department of Veterinary Services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Malaysia has a parallel Traditional and Complementary Medicine Division within the Ministry of Health; whether leech therapy is regulated under T&CM or as a medical device has not been independently verified.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.